Relapse after allogeneic stem cell transplantation
AJ Barrett, M Battiwalla - Expert review of hematology, 2010 - Taylor & Francis
Since allogeneic stem cell transplantation (SCT) represents an intensive curative treatment
for high-risk malignancies, its failure to prevent relapse leaves few options for successful …
for high-risk malignancies, its failure to prevent relapse leaves few options for successful …
[HTML][HTML] DNA methylation: its role in cancer development and therapy
C Kurkjian, S Kummar, AJ Murgo - Current problems in cancer, 2008 - ncbi.nlm.nih.gov
Changes in the genome which result in cancer promotion remain a complex interplay of
aberrant methylation in the setting of a multitude of epigenetic changes. The events leading …
aberrant methylation in the setting of a multitude of epigenetic changes. The events leading …
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic …
M Lübbert, H Bertz, R Wäsch, R Marks… - Bone marrow …, 2010 - nature.com
We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte
infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia …
infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia …
Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery
Histone proteins are subject to a diverse range of post-translational modifications which,
along with DNA methylation, play a major role in controlling gene expression, cell division …
along with DNA methylation, play a major role in controlling gene expression, cell division …
Management of relapse after allo-SCT for AML and the role of second transplantation
BN Savani, S Mielke, N Reddy, S Goodman… - Bone marrow …, 2009 - nature.com
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although
curative, is not an appropriate treatment option for a large number of relapsing patients (only …
curative, is not an appropriate treatment option for a large number of relapsing patients (only …
Decitabine in the treatment of myelodysplastic syndromes
FPS Santos, H Kantarjian… - Expert review of …, 2010 - Taylor & Francis
Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem
cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias and a …
cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias and a …
Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute …
M Van Gelder, LC De Wreede, J Schetelig… - Leukemia, 2013 - nature.com
Abstract Treatment algorithms for poor cytogenetic-risk myelodysplastic syndrome (MDS),
defined by chromosome 7 abnormalities or complex karyotype (CK), include allogeneic stem …
defined by chromosome 7 abnormalities or complex karyotype (CK), include allogeneic stem …
Decitabine
B Hackanson, M Daskalakis - Small Molecules in Oncology, 2014 - Springer
Abstract Besides 5-azacytidine (azacitidine, Vidaza®), 5-aza-2′-deoxycytidine (decitabine,
Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers …
Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers …
[HTML][HTML] NCI first international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the …
EP Alyea, DJ DeAngelo, J Moldrem, JM Pagel… - Biology of Blood and …, 2010 - Elsevier
Prevention of relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is the
most likely approach to improve survival of patients treated for hematologic malignancies …
most likely approach to improve survival of patients treated for hematologic malignancies …
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous …
C Hosing, RM Saliba, M Shahjahan, EH Estey… - Bone marrow …, 2005 - nature.com
The major cause of failure after allogeneic hematopoietic stem cell transplantation (HSCT)
for acute myelogenous leukemia (AML) is disease relapse or progression. We analyzed the …
for acute myelogenous leukemia (AML) is disease relapse or progression. We analyzed the …